Using the PEG framework with analyst consensus forward EPS growth of 25.0% plus 7.3% dividend yield, Healthpeak Properties, Inc. has a fair value of $5.96 based on NTM EPS (FY2026) of $0.24. The current PEG ratio is 1.35.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
Growth above 25% is capped — hypergrowth may not be sustainable long-term.
| EPS Growth RateForward | 45.0% |
| Dividend Yield | +7.3% |
| Adjusted Growth (clamped 8–25%)Clamped | 25.0% |
| Fair P/E | 25.0x |
| NTM EPS (FY2026) | $0.24 |
| Fair Value | $5.96 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $0.10 | — | — |
| FY2026E | $0.24 | +138.6% | 6 |
| FY2027E | $0.29 | +19.8% | 8 |
| FY2028E | $0.30 | +6.7% | 6 |
3Y Forward EPS CAGR: 45.0%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $505.5M | $0.93 | — |
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.
| FY2022 | $500.4M | $0.92 | -1.1% |
| FY2023 | $306.0M | $0.56 | -39.1% |
| FY2024 | $243.1M | $0.36 | -35.7% |
| FY2025 | $71.3M | $0.10 | -72.2% |
4Y Historical EPS CAGR: -42.7%